Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial

Open Forum Infectious Diseases
Mark J MulliganRichard Gorman

Abstract

Avian influenza A/H5N1 has threatened human health for nearly 2 decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid tactic for mass vaccination will be needed if a pandemic occurs. A multicenter, randomized, blinded phase 1 clinical trial evaluated safety and antibody responses after point-of-use mixing of influenza A/Indonesia/05/2005 (H5N1) vaccine with MF59 adjuvant. Field-site pharmacies mixed 3.75, 7.5, or 15 mcg of antigen with or without MF59 adjuvant just prior to intramuscular administration on days 0 and 21 of healthy adults aged 18-49 years. Two hundred and seventy subjects were enrolled. After vaccination, titers of hemagglutination inhibition antibody ≥1:40 were achieved in 80% of subjects receiving 3.75 mcg + MF59 vs only 14% receiving 15 mcg without adjuvant (P < .0001). Peak hemagglutination inhibition antibody geometric mean titers for vaccine + MF59 were ∼65 regardless of antigen dose, and neutralizing titers were 2- to 3-fold higher. Vaccine + MF59 produced cross-reactive antibody responses against 4 heterologous H5N1 viruses. Excellent safety and tolerability were demonstrated. Point-of-use mixing of H5N1 antigen and MF59 adjuvant achieved target antibody titers in a h...Continue Reading

References

Jun 25, 1998·Cellular Immunology·M DupuisD M McDonald
Mar 31, 2006·The New England Journal of Medicine·John J TreanorMark Wolff
Nov 25, 2006·The New England Journal of Medicine·Robert G Webster, Elena A Govorkova
Jan 18, 2008·The New England Journal of Medicine·UNKNOWN Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian InfTimothy M Uyeki
Feb 12, 2008·The Journal of Infectious Diseases·David I BernsteinHeather Hill
Apr 9, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anja SeubertAndreas Wack
Jul 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·F MoscaE De Gregorio
Feb 20, 2009·Clinical and Vaccine Immunology : CVI·Diana L NoahMark C Wolff
Sep 12, 2009·The New England Journal of Medicine·Tristan W ClarkIain Stephenson
Aug 20, 2010·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food And Drug Administration
Nov 26, 2010·Sleep·Yves DauvilliersEmmanuel Mignot
Feb 2, 2011·The Journal of Infectious Diseases·Robert B BelsheUNKNOWN National Institute of Allergy and Infectious Diseases-Funded Vaccine and Treatment Evaluation Units
Oct 15, 2011·The New England Journal of Medicine·Timo VesikariRalf Clemens
May 17, 2013·Science Translational Medicine·Philip R DormitzerJ Craig Venter
Jun 4, 2013·Virus Research·Mariana BazKanta Subbarao
Feb 28, 2014·The Lancet Infectious Diseases
May 3, 2014·Science Translational Medicine·Stephan A BartNiranjan Kanesa-Thasan
Mar 4, 2015·Open Forum Infectious Diseases·Paul E Sax

❮ Previous
Next ❯

Citations

Apr 27, 2016·Nanomedicine : Nanotechnology, Biology, and Medicine·Weiping CaoSuryaprakash Sambhara
Sep 24, 2016·Cell·Keith PardeeJames J Collins
Nov 10, 2018·Nature Reviews. Disease Primers·Massimo FilippiMaria A Rocca

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01317745

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.